Table 1.
Baseline characteristics of patients based on time of granulocyte colony-stimulating factor (GCSF) initiation.
| Characteristic | Day +1 group (N=100) |
Day +5 group (N=100) |
P-value |
|---|---|---|---|
|
Gender, n (%)
Female Male |
41 (41.0%) 59 (59.0%) |
45 (45.0%) 55 (55.0%) |
0.57 |
| Age, years (median, IQR) | 38.5 (25.25 – 51.0) | 46.5 (29.0 – 52.0) | 0.049 |
| BMI, kg/m2 (mean ± SD) | 26.97 (5.5) | 26.6 (5.2) | 0.66 |
|
Underlying malignancy, n (%)
Multiple myeloma Hodgkin’s lymphoma Non-Hodgkin’s lymphoma Solid tumor Acute myeloid leukemia |
35 (35.0%) 38 (38.0%) 23 (23.0%) 3 (3.0%) 1 (1.0%) |
50 (50.0%) 35 (3.0%) 12 (12.0%) 1 (1.0%) 2 (2.0%) |
0.086 |
|
Conditioning regimens, n (%)
CEAM1 HD Melphalan2 Bu-Mel3 HD ICE4 Bu-Mel 5 |
61 (61.0%) 34 (34.0%) 0 (0.0%) 3 (3.0%) 1 (1.0%) |
47 (47.0%) 49 (49.0%) 1 (1.0%) 0 (0.0%) 2 (2.0%) |
0.026 |
| History of radiation therapy, n (%) | 37 (37.0%) | 30 (30.0%) | 0.37 |
|
Chemotherapy line, n (%)
<2 ≥2 |
71 (71.0%) 29 (29.0%) |
82 (82.0%) 18 (18.0%) |
0.075 |
|
CD34+ cell count, *106/kg (median, IQR)
Harvested CD34+ cell Infused CD34+ cell |
3.7 (1 – 4.7) 3.7 (1.2 – 4.9) |
3.6 (1.0 – 4.6) 3.5 (1.0 – 4.5) |
0.11 0.08 |
|
Disease remission status
Partial remission Complete remission |
38 (38.0%) 62 (62.0%) |
45 (45.0%) 55 (55.0%) |
0.31 |
BMI, body mass index; IQR, interquartile range; N, number; SD, standard deviation; CEAM, CCNU, Etoposide, Cytarabine, and Melphalan; MM, Multiple myeloma; HD, high dose; Bu-Mel, busulfan-Melphalan; ICE, Ifosfamide, Carboplatin and Etoposide.
1Regimen for patients with NHL Hodgkin’s disease; 2Regimen for patients with Multiple Myeloma; 3Regimen for patients with Ewing sarcoma; 4Regimen for patients with Germ Cell Tumors; 5Regimen for patients with Acute Myeloid Leukemia.